The Pharma Data

JANUARY 13, 2021

CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. CD40-ligand is also known as CD154, the T cell-B cell activating molecule (T-BAM), TRAP and gp39. 175:1091-1101 (1992) 2 Karpusas, M et al., International Immunol. (11):1583 Structure. 9(4):321-9.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

Conversations in Drug Development Trends

MAY 30, 2024

Differences in regulatory sentiments and industry sponsors’ subsequent clinical development strategies historically restricted access based on geography. However, work is needed before CRISPR-mediated treatments become possible, including a better understanding of the genes involved in ALS.

Treatment 81

Treatment Small Molecule Clinical Trials Therapies 81

Alta Sciences

APRIL 17, 2024

They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression. And since proteins are often linked to disease, there's huge potential to treat a broad range of diseases with this technology. Asia, and Europe.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

Drug Discovery World

NOVEMBER 13, 2023

Michael Traxlmayr, PhD, Group leader, CD Laboratory for Next-Generation CAR T Cells, University of Natural Resources & Life Sciences, on: ‘Novel concepts to regulate CAR T cell activity with small molecule drugs in vivo’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147

The Pharma Data

SEPTEMBER 2, 2020

Roche’s commitment to potentially slow or stop disease progression continues with the Phase III clinical trial programme initiation of fenebrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor in RMS and PPMS. The Phase III clinical development programme for ENSPRYNG includes two studies: SAkuraStar and SAkuraSky.

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52